United Neuroscience reports Phase I data for AD vaccine UB-311

United Neuroscience Inc. (Hauppauge, N.Y.) said UB-311 led to a 100% responder rate in a Phase I trial in 19 patients ages 50-80 with mild to moderate Alzheimer’s disease. A responder was defined as achieving any increase from baseline in anti-beta amyloid antibody titers. UB-311 was well tolerated with injection-site swelling and agitation reported as the most common adverse events. Data were published in Alzheimer's & Dementia: Translational Research & Clinical Interventions. The 48-week, open-label, Taiwanese trial evaluated the safety and immunogenicity of a 300 µg dose of intramuscular UB-311 given at weeks 0, 4 and 12.

UB-311 is an endobody vaccine targeting beta amyloid designed to induce high B cell specific responses while avoiding T cell inflammation. Data from a Phase II trial of UB-311 to treat early to mild AD are expected in mid-2018...